
AleÅ; Å orf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1355189/publications.pdf Version: 2024-02-01



Δι εΔ: Δορε

#	Article	IF	CITATIONS
1	Dabrafenib inhibits ABCC2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicology and Applied Pharmacology, 2022, 434, 115797.	2.8	4
2	ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia. Biomedicine and Pharmacotherapy, 2022, 150, 112962.	5.6	4
3	Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. Cancers, 2020, 12, 1596.	3.7	13
4	S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is Not a Selective Inhibitor of Equilibrative Nucleoside Transporters but Also Blocks Efflux Activity of Breast Cancer Resistance Protein. Pharmaceutical Research, 2020, 37, 58.	3.5	4
5	Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics. Drug Metabolism and Disposition, 2019, 47, 954-960.	3.3	13
6	Brivanib Exhibits Potential for Pharmacokinetic Drug–Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Molecular Pharmaceutics, 2019, 16, 4436-4450.	4.6	22
7	Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metabolism and Disposition, 2019, 47, 699-709.	3.3	15
8	Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochemical Pharmacology, 2019, 163, 290-298.	4.4	9
9	Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochemical Pharmacology, 2018, 154, 10-17.	4.4	41
10	In vitro and in silico Evaluation of Non-Quaternary Reactivators of AChE as Antidotes of Organophosphorus Poisoning - a New Hope or a Blind Alley?. Medicinal Chemistry, 2018, 14, 281-292.	1.5	19